BIO three-lens brief
Evidence-based stock research on BIO. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 26.5pp over 30 days. · RSI at 29 — technically oversold.
- RSI at 29 — technically oversold.
- Underperforming SPY by 26.5pp over 30 days.
- Analyst mean target $286.25 — 18% above current (4 analysts).
- Debt-to-equity of 20.1 — balance-sheet-heavy.
BIO closed at $242.11 (+0.17%) as of 2026-05-13. Market cap: $6.48B. P/E (trailing) 40.2. Positives: analyst mean target $286.25 — 18% above current (4 analysts).. Concerns: rSI at 29 — technically oversold.; underperforming SPY by 26.5pp over 30 days.. Last quarter: Revenue $592.10M, net income $0.00, free cash flow $229.76M.
Why three lenses on BIO, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BIOacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BIO" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BIO brief"></iframe>